LDP-341
Showing 1 - 25 of 172
Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Jacksonville, Florida
- +1 more
Jan 5, 2023
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +4 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Aug 5, 2022
Lymphoma Trial in Duarte, South Pasadena (biological, drug, other)
Active, not recruiting
- Lymphoma
- rituximab
- +3 more
-
Duarte, California
- +1 more
Feb 28, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Los Angeles, California
- +1 more
Aug 19, 2022
Plasma Cell Myeloma, Renal Failure Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Renal Failure
- Bortezomib
- +4 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jun 13, 2022
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
-
Duarte, CaliforniaCity of Hope
Mar 17, 2022
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in
Completed
- Contiguous Stage II Mantle Cell Lymphoma
- +5 more
- bortezomib
- +9 more
-
Duarte, California
- +1 more
Jan 12, 2022
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Acute Lymphoblastic Leukemia Trial in Canada, United States (ITMHA, Dexamethasone, Mitoxantrone)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- ITMHA
- +13 more
-
Los Angeles, California
- +17 more
Jun 6, 2022
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
Completed
- Adenocarcinoma of the Gastroesophageal Junction
- +7 more
-
Bronx, New YorkMontefiore Medical Center
Jan 29, 2021
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Mantle Cell Lymphoma Trial in Houston (Bortezomib, Cyclophosphamide, Cytarabine)
Completed
- Mantle Cell Lymphoma
- Bortezomib
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Indianapolis, Rochester, Wauwatosa (Bortezomib,
Withdrawn
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Indianapolis, Indiana
- +2 more
Sep 29, 2020
Refractory Multiple Myeloma Trial in Scottsdale, Jacksonville, Rochester (pomalidomide, bortezomib, dexamethasone)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial in Houston (Bortezomib, Carboplatin, Etoposide)
Completed
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Bortezomib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Apr 9, 2020
High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in New Brunswick
Withdrawn
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- +6 more
- Bortezomib
- +2 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jun 12, 2020